We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Editas

News List

CRISPR therapies could be one of the most transformative in human history, says GlobalData europeanpharmaceuticalreview
March 17, 2021
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
Editas and BlueRock partner to develop engineered cell medicines pharmaceutical-technology
April 23, 2019
Editas and BlueRock partner to develop engineered cell medicines.
Editas bags $25M from Allergan as FDA signs off on human CRISPR trial fiercebiotech
January 03, 2019
After a year’s delay, Editas Medicine is finally back on track. The gene-editing biotech announced Friday the FDA has OK’d its IND application and that it will start enrolling patients in a phase 1/2 trial of ......
Allergan and Editas Medicine Enter to Discover and Develop CRISPR Genome Editing Medicines for Eye D americanpharmaceuticalreview
March 15, 2017
Allergan and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine's genome-editing ocular programs, including its lead pr